Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a significant revenue increase for its TTR franchise, projecting 83% growth in 2026, with total global TTR revenues reaching $2.1 billion since the ATTR-CM launch. Alnylam estimates nearly 200,000 ATTR-CM patients in the U.S., with over 80% untreated.